Key result
Accumulating minor clinical covariates drives supratherapeutic DOAC exposure in pharmacokinetic simulations.
Why the study?
DOAC plasma concentration is linked to clinical and bleeding events, making population pharmacokinetic analyses valuable for identifying influencing factors and providing predictive models.
Does the accumulation of minor pharmacokinetic covariates increase DOAC exposure to supratherapeutic levels in simulated patients?
Systematic Review
Does the accumulation of minor pharmacokinetic covariates increase DOAC exposure to supratherapeutic levels in simulated patients?
Current DOAC dose adjustments may be inadequate because they do not account for the cumulative effect of seemingly minor covariates like drug-drug interactions and genotypes, which together can cause dangerous overexposure.
Answers are grounded in this paper and cite their sources.
Minor covariate accumulation may require adjusted DOAC dosing; extends simulations to challenge current thresholds for prospective validation.
Available data have shown an association between direct oral anticoagulant (DOAC) plasma concentration and clinical, particularly bleeding, events. Factors that may influence DOAC plasma concentration are therefore the focus of particular attention. Population pharmacokinetic (PopPK) analyses can help in identifying such factors while providing predictive models. The main aim of the present study was to identify all the PopPK models to date for the four most frequently used DOACs (dabigatran, apixaban, rivaroxaban, and edoxaban). The secondary aim was to use these models to simulate different DOAC plasma concentration-time profiles in relevant clinical scenarios. The results of our model-based simulations confirm the clinical relevance of the known major factors influencing DOAC exposure and support the current approved dose adaptation, at least for atrial fibrillation. They also highlight how the accumulation of covariates, not currently considered for dose adaptation due to their seemingly minor influence on DOAC exposure, lead to supratherapeutic blood concentrations and could thus enhance the risk of major bleeding. The present results therefore question DOAC dose adaptation in the presence of these covariates, such as drug-drug interaction or genotypes, alongside the known existing covariates. As the overall effect of accumulation of several covariates could be difficult to apprehend for the clinicians, PopPK modeling could represent an interesting approach for informed precision dosing and to improve personalized prescription of DOACs.
No takes yet. Share an insight, caveat, or question.
Terrier et al. (2022) conducted a systematic review in Atrial fibrillation, venous thromboembolism, or healthy volunteers (pharmacokinetic models). Direct oral anticoagulants (dabigatran, apixaban, rivaroxaban, edoxaban) vs. Typical simulated patient with normal renal function (CrCL 100 mL/minute) and no concomitant interacting treatments was evaluated on Drug exposure (Area Under the Curve, AUC) and apparent clearance (CL/F). Model-based simulations demonstrated that the accumulation of minor patient covariates (such as mild drug interactions or genotypes) leads to supratherapeutic DOAC blood concentrations.
Synapse has enriched 10 related papers. Consider them for comparative context: